Cargando…

Inhibition of Eukaryotic Translation Elongation by Cycloheximide and Lactimidomycin

Although the protein synthesis inhibitor cycloheximide (CHX) has been known for decades, its precise mechanism of action remains incompletely understood. The glutarimide portion of CHX is seen in a family of structurally related natural products including migrastatin, isomigrastatin and lactimidomyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider-Poetsch, Tilman, Ju, Jianhua, Eyler, Daniel E, Dang, Yongjun, Bhat, Shridhar, Merrick, William C, Green, Rachel, Shen, Ben, Liu, Jun O
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831214/
https://www.ncbi.nlm.nih.gov/pubmed/20118940
http://dx.doi.org/10.1038/nchembio.304
Descripción
Sumario:Although the protein synthesis inhibitor cycloheximide (CHX) has been known for decades, its precise mechanism of action remains incompletely understood. The glutarimide portion of CHX is seen in a family of structurally related natural products including migrastatin, isomigrastatin and lactimidomycin (LTM). LTM, isomigrastatin and analogs were found to have a potent antiproliferative effect on tumor cell lines and selectively inhibit protein translation. A systematic comparative study of the effects of CHX and LTM on protein translation revealed both similarities and differences between the two inhibitors. Both LTM and CHX were found to block the translocation step in elongation. Footprinting experiments revealed protection of a single cytidine nucleotide (C3993) in the E-site of the 60S ribosomal subunit, defining a common binding pocket for both inhibitors in the ribosome. These results shed new light on the molecular mechanism of inhibition of translation elongation by both CHX and LTM.